10x Genomics, Inc. et al. v. Vizgen, Inc.

Case Overview and Background

This patent infringement case represented a high-stakes battle in the rapidly evolving and intensely competitive field of spatial biology, pitting established genomics company 10x Genomics against a newer rival, Vizgen. The plaintiffs were 10x Genomics, a major life sciences technology company that develops and sells instruments and software for single-cell and spatial analysis, and the President and Fellows of Harvard College, the university entity responsible for licensing its intellectual property. The defendant, Vizgen, is a venture-backed life sciences company founded in 2019 out of Harvard University to commercialize a specific spatial genomics technology. The core of the dispute was 10x and Harvard's claim that Vizgen's commercial platform infringed on patents exclusively licensed to 10x by Harvard. This legal fight was part of a broader, multi-front patent war initiated by 10x to enforce its intellectual property in the spatial transcriptomics market, a sector seeing explosive growth and innovation.

The technology at issue revolves around methods for in-situ analysis of nucleic acids, which allows researchers to map the precise location of RNA molecules within cells and tissues. This "spatial transcriptomics" provides critical insights into cellular function and disease that are lost in traditional sequencing methods. The lawsuit, filed in May 2022, initially accused Vizgen's MERSCOPE® Platform of infringing five Harvard-owned patents. The MERSCOPE platform is Vizgen's flagship product and the first commercially available platform to leverage MERFISH (multiplexed error-robust fluorescence in situ hybridization) technology, enabling researchers to image hundreds of genes at subcellular resolution. One of the key patents asserted was U.S. Patent No. 11,021,737, which generally covers methods for detecting individual nucleic acid molecules in cells using combinatorial labeling and imaging. The case was litigated in the U.S. District Court for the District of Delaware, a premier venue for patent disputes due to its experienced judiciary and well-developed body of case law. The case was initially assigned to Judge Matthew F. Kennelly, though other judges in the district like Gregory B. Williams also handle a significant number of patent cases.

The case was notable not only for the conflict between two key players in spatial biology but also for Vizgen's aggressive defense and counterclaims. Vizgen argued the patents were invalid and not infringed, and additionally filed counterclaims alleging that 10x and Harvard had engaged in anticompetitive behavior by attempting to monopolize the market in violation of antitrust laws. Vizgen contended that Harvard had breached its obligations under a grant from the National Institutes of Health (NIH) by providing an exclusive license to 10x, thereby stifling competition. The dispute escalated, with potential infringement damages for 10x estimated at over $9 million and Vizgen seeking hundreds of millions in its antitrust case. The litigation drew significant attention within the biotech industry, which was already wary of the chilling effect of extensive patent litigation on innovation. Ultimately, the parties reached a global settlement on February 5, 2025, four days into a jury trial, resolving all related U.S. and European litigation. While the terms were not disclosed, the settlement ended a contentious chapter and underscored the critical importance of intellectual property in the cutting-edge genomics sector.

Legal Developments and Outcome

This litigation featured a patent infringement suit by 10x Genomics and Harvard University, which was met with substantial counterclaims from Vizgen, Inc., including claims of non-infringement, patent invalidity, breach of contract, and significant antitrust violations. The dispute ultimately resolved mid-trial through a global settlement.

Filing & Initial Pleadings (2022-2023)

• 2022-05-04: Complaint Filed
  10x Genomics, Inc. and its licensor, President and Fellows of Harvard College, filed a patent infringement lawsuit against Vizgen, Inc. in the District of Delaware. The complaint initially asserted five patents, including U.S. Patent No. 11,021,737, related to in-situ gene analysis technology. The plaintiffs alleged that Vizgen's MERSCOPE® platform infringed these patents.

• 2022-08-30: Answer and Counterclaims
  Vizgen filed its answer, denying infringement and asserting a host of counterclaims. Beyond seeking a declaratory judgment of non-infringement and invalidity of the asserted patents, Vizgen accused 10x and Harvard of attempting to monopolize the spatial genomics market. The counterclaims also included allegations of breach of contract by Harvard related to its licensing practices and tortious interference by 10x. Vizgen also asserted its own patent, U.S. Patent No. 11,098,303 (the "'303 patent"), against 10x's Xenium platform.

• 2023-04-25: Amended Pleadings
  The case saw multiple amended pleadings. Notably, by April 2023, Vizgen filed its Answer, Defenses, and Counterclaims to the Plaintiffs' Second Amended Complaint (D.I. 148), which further detailed its allegations. These included claims that Harvard breached the implied covenant of good faith and fair dealing in its license agreement with Vizgen and that 10x and Harvard engaged in unfair and deceptive trade practices.

Pre-Trial Motions & Rulings (2023-2025)

• 2023-02-02: Ruling on Motions to Dismiss
  Judge Matthew F. Kennelly issued a Memorandum Opinion and Order on 10x and Harvard's motions to dismiss Vizgen's amended counterclaims (D.I. 114). The court denied the motions with respect to several key claims, including breach of the implied covenant of good faith (Count 1), tortious interference (Count 4), and violations of Massachusetts statutes (Count 5), allowing them to proceed into discovery. However, other counterclaims were dismissed.

• 2024-05-06: Vizgen Expands Antitrust Case
  The court granted a motion by Vizgen to amend its counterclaims to include additional antitrust allegations. These new claims were based on evidence uncovered during discovery and included accusations of unlawful bundling of 10x's established products with its newer Xenium platform, as well as predatory pricing. This ruling led to an extension of the case schedule, with a new trial date set for early February 2025.

• 2025-01-03: Summary Judgment Ruling
  In a significant pre-trial development, Judge Kennelly issued a ruling on the parties' cross-motions for summary judgment (referenced in multiple reports published Jan. 6, 2025). The court granted summary judgment in favor of 10x and Harvard on Vizgen's key federal antitrust counterclaims under the Sherman Act, finding insufficient evidence of an unlawful conspiracy to monopolize the market. However, the court denied summary judgment on several of Vizgen's other counterclaims, including Harvard's alleged breach of the implied covenant of good faith and fair dealing and 10x's alleged tortious interference related to certain discounting practices. The court also denied Vizgen's motion for summary judgment on the invalidity of the asserted patents, ensuring that both the infringement claims and the remaining counterclaims would proceed to a jury trial.

Parallel PTAB Proceedings (2023-2024)

• 2023-08-30: IPR Petition Filed by 10x
  10x Genomics filed a petition for inter partes review (IPR) with the Patent Trial and Appeal Board (PTAB) against U.S. Patent No. 11,098,303, which Vizgen had asserted in its counterclaims. The IPR was docketed as IPR2023-01299.

• 2024-03-07: PTAB Denies Institution of IPR
  The PTAB denied institution of the IPR filed by 10x. The Board found 10x's petition deficient and determined there was not a "reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged." The denial was also based in part on the advanced state of the parallel district court litigation, under the Fintiv framework. This was a significant victory for Vizgen, as it preserved the '303 patent for its counterclaim in the district court case. No records indicate that Vizgen filed any IPRs against the 10x/Harvard patents-in-suit.

Trial, Settlement & Dismissal (2025)

• 2025-02-03: Jury Trial Commences
  A jury trial began in the District of Delaware before Judge Kennelly.

• 2025-02-06: Mid-Trial Settlement and Dismissal
  After three to four days of trial, during which 10x and Harvard presented their case-in-chief, the parties reached a global settlement resolving all pending litigation between them in the U.S. and Europe. The parties filed a joint stipulation of dismissal with prejudice. Each party agreed to bear its own legal fees and costs, and the specific financial terms of the settlement were not publicly disclosed. The case was officially terminated on the court docket.

Below is a detailed list of the counsel of record for the plaintiffs, 10x Genomics, Inc. and President and Fellows of Harvard College, in their patent infringement lawsuit against Vizgen, Inc.

Counsel for Plaintiff 10x Genomics, Inc.

Tensegrity Law Group LLP served as lead counsel for 10x Genomics, bringing a team of seasoned patent litigators from its California and Virginia offices.

• Matthew D. Powers | Lead Counsel

  • Firm: Tensegrity Law Group LLP (Redwood Shores, CA)
  • Note: A nationally recognized trial lawyer, Powers is a founding partner of Tensegrity and has won numerous high-stakes patent and technology cases across the country and at the ITC.

• Paul T. Ehrlich | Lead Counsel

  • Firm: Tensegrity Law Group LLP (Redwood Shores, CA)
  • Note: A founding partner, Ehrlich has extensive experience in complex patent trials in U.S. district courts and the ITC, covering technologies from biotechnology to computer networking.

• Stefani C. Smith | Of Counsel

  • Firm: Tensegrity Law Group LLP (Redwood Shores, CA)
  • Note: Smith has significant experience in patent, trade secret, and contract litigation in federal court and the ITC, representing clients in biotech, medical devices, and other high-tech fields.

Additional attorneys from Tensegrity who appeared pro hac vice include Li Shen, Kiley White, Robert L. Gerrity, Ronald J. Pabis, and Samantha A. Jameson.

Morris, Nichols, Arsht & Tunnell LLP acted as Delaware local counsel for 10x Genomics.

• Karen Jacobs | Local Counsel

  • Firm: Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)
  • Note: Jacobs is a veteran IP litigator with over three decades of experience, focusing on patent infringement cases in Delaware's district court across a range of industries.

• Cameron P. Clark | Local Counsel

  • Firm: Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)
  • Note: An associate in the firm's IP Litigation group, Clark's practice centers on patent, copyright, and trademark cases.

Counsel for Plaintiff President and Fellows of Harvard College

Foley & Lardner LLP served as lead counsel for Harvard College.

• Geoffrey M. Raux | Lead Counsel
  • Firm: Foley & Lardner LLP (Boston, MA)
  • Note: Raux is a commercial litigator with significant trial experience in federal and state courts, handling complex disputes involving licensing, business torts, and healthcare matters.

Morris James LLP acted as Delaware local counsel for Harvard College.

• Kenneth L. Dorsney | Local Counsel

  • Firm: Morris James LLP (Wilmington, DE)
  • Note: As chair of his firm's Intellectual Property Practice, Dorsney is a registered patent attorney with extensive experience in complex patent, trademark, and trade secret litigation in Delaware.

• Cortlan S. Hitch | Local Counsel

  • Firm: Morris James LLP (Wilmington, DE)
  • Note: Hitch's practice is focused on patent and trademark litigation, frequently representing clients in high-profile patent disputes and Hatch-Waxman litigation in the District of Delaware.

Defendant's Counsel of Record

Vizgen, Inc. was represented by attorneys from several prominent law firms, including Quinn Emanuel Urquhart & Sullivan LLP as lead counsel and Farnan LLP as local counsel in Delaware.

Quinn Emanuel Urquhart & Sullivan LLP (Lead Counsel)

• Name: E. Joshua Rosenkranz

  • Role: Lead Counsel
  • Firm & Office: Quinn Emanuel Urquhart & Sullivan LLP, New York, NY
  • Note: Co-chair of the firm's national appellate practice, Rosenkranz is a renowned appellate litigator who has argued numerous high-stakes cases before the U.S. Supreme Court and federal appeals courts.

• Name: Elaine J. Goldenberg

  • Role: Of Counsel
  • Firm & Office: Quinn Emanuel Urquhart & Sullivan LLP, Washington, D.C.
  • Note: As co-chair of the firm's national appellate practice, she has extensive experience arguing complex cases, including intellectual property disputes, before the Supreme Court and Federal Circuit.

• Name: Ginger D. Anders

  • Role: Of Counsel
  • Firm & Office: Quinn Emanuel Urquhart & Sullivan LLP, Washington, D.C.
  • Note: Formerly an Assistant to the Solicitor General at the U.S. Department of Justice, Anders has argued over 20 cases in the U.S. Supreme Court, many involving patent law.

• Name: David A. Perlson

  • Role: Of Counsel
  • Firm & Office: Quinn Emanuel Urquhart & Sullivan LLP, San Francisco, CA
  • Note: A seasoned trial lawyer, Perlson has led major intellectual property and antitrust cases for leading technology companies, securing significant victories in jury trials.

• Name: Matthew A. Traupman

  • Role: Of Counsel
  • Firm & Office: Quinn Emanuel Urquhart & Sullivan LLP, Boston, MA
  • Note: Focuses on high-stakes patent litigation in the life sciences and technology sectors.

• Name: Elizabeth L. Deeley

  • Role: Of Counsel
  • Firm & Office: Quinn Emanuel Urquhart & Sullivan LLP, San Francisco, CA
  • Note: Specializes in complex commercial litigation, including intellectual property and antitrust matters for technology and biotech clients.

Farnan LLP (Local Counsel)

• Name: Joseph B. Farnan, Jr.

  • Role: Local Counsel
  • Firm & Office: Farnan LLP, Wilmington, DE
  • Note: A former federal judge for the District of Delaware, he now provides counsel in complex commercial litigation and serves as a mediator and arbitrator.

• Name: Brian E. Farnan

  • Role: Local Counsel
  • Firm & Office: Farnan LLP, Wilmington, DE
  • Note: Represents clients in a wide range of intellectual property and commercial litigation matters before the District of Delaware.

• Name: Michael J. Farnan

  • Role: Local Counsel
  • Firm & Office: Farnan LLP, Wilmington, DE
  • Note: Focuses his practice on patent and complex commercial litigation in Delaware's federal and state courts.